NASDAQ: OLMAOlema Pharmaceuticals Inc Stock
$10.15+0.15 (+1.5%)
Updated Apr 24, 2024
OLMA Price
$10.15
Fair Value Price
$1.46
Market Cap
$567.53M
52 Week Low
$3.93
52 Week High
$17.79
P/E
-4.74x
P/B
2.24x
P/S
N/A
PEG
N/A
Dividend Yield
N/A
Revenue
$0.00
Earnings
-$96.66M
Gross Margin
N/A
Operating Margin
N/A
Profit Margin
N/A
Debt to Equity
0.09
Operating Cash Flow
-$84M
Beta
1.49
Next Earnings
May 7, 2024
Ex-Dividend
N/A
Next Dividend
N/A
OLMA Overview
Olema Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapies for women's cancers. Its lead product candidate is OP-1250, an estrogen receptor (ER) antagonist and a selective ER degrader, which is in Phase 1/2 clinical trial for the treatment of recurrent, locally advanced, or metastatic estrogen receptor-positive, human epidermal growth factor receptor 2-negative breast cancer. The company was formerly known as CombiThera, Inc. and changed its name to Olema Pharmaceuticals, Inc. in March 2009. Olema Pharmaceuticals, Inc. was incorporated in 2006 and is headquartered in San Francisco, California.
Zen Score
–
Industry Average (23)
You've viewed Zen Score for 10/10 free stocks. Upgrade to Premium to see how OLMA scored across 33 valuation, financial, forecast, performance, and dividend due diligence checks.
Due Diligence Checks
OLMA ($10.15) is overvalued by 594.56% relative to our estimate of its Fair Value price of $1.46 based on Discounted Cash Flow (DCF) modelling
Below Fair Value Valuation
OLMA ($10.15) is not significantly undervalued (594.56%) relative to our estimate of its Fair Value price of $1.46 based on Discounted Cash Flow (DCF) modelling, when including a healthy margin of safety
Significantly Below Fair Value Valuation
OLMA is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation
There are 30 more OLMA due diligence checks available for Premium users.
Be the first to know about important OLMA news, forecast changes, insider trades & much more!
OLMA News
Valuation
OLMA fair value
Fair Value of OLMA stock based on Discounted Cash Flow (DCF)
Price
$10.15
Fair Value
$1.46
Overvalued by
594.56%
OLMA ($10.15) is overvalued by... subscribe to Premium to read more.
Below Fair Value Valuation
OLMA ($10.15) is not significantly... subscribe to Premium to read more.
Significantly Below Fair Value Valuation
OLMA is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation
OLMA price to earnings (PE)
For valuing profitable companies with steady earnings
Company
-4.74x
Industry
15.69x
Market
41.27x
OLMA price to book (PB)
For valuing companies that are loss-making or have lots of physical asset
Company
2.24x
Industry
5.86x
OLMA is good value based... subscribe to Premium to read more.
P/B vs Industry Valuation
OLMA's financial health
Profit margin
Revenue
$0.0
Net Income
-$26.8M
Profit Margin
0%
OLMA's cash burn is expected... subscribe to Premium to read more.
Interest Coverage Financials
Assets to liabilities
Assets
$276.9M
Liabilities
$23.1M
Debt to equity
0.09
OLMA's short-term assets ($266.51M) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
OLMA's short-term assets ($266.51M) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
OLMA's debt has increased relative... subscribe to Premium to read more.
Shrinking Debt Financials
OLMA's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials
Cash flow
Operating
-$18.5M
Investing
-$30.9M
Financing
$523.0k
OLMA's cash and short-term investments... subscribe to Premium to read more.
Debt Coverage Financials
OLMA vs Biotech Stocks
Olema Pharmaceuticals Stock FAQ
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsHelp GuidesContactTwitterYouTubeNewsletterWallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.